First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.

Carol Moreno; Richard Greil; Fatih Demirkan; Alessandra Tedeschi; Bertrand Anz; Loree Larratt; Martin Simkovic; Jan Novak; Vladimir Strugov; Devinder Gill; John G Gribben; Kevin Kwei; Sandra Dai; Emily Hsu; James P Dean; Ian W Flinn

doi:10.3324/haematol.2021.279012

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.

Carol Moreno, Richard Greil (Co-author), Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz, Loree Larratt, Martin Simkovic, Jan Novak, Vladimir Strugov, Devinder Gill, John G Gribben, Kevin Kwei, Sandra Dai, Emily Hsu, James P Dean, Ian W Flinn

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

87 Citations (Web of Science)

Original language	English
Pages (from-to)	2108-2120
Journal	HAEMATOLOGICA
Volume	107
Issue number	9
DOIs	https://doi.org/10.3324/haematol.2021.279012
Publication status	Published - 2022

Keywords

OPEN-LABEL
CHEMOIMMUNOTHERAPY
MULTICENTER
RITUXIMAB
OUTCOMES

Access to Document

10.3324/haematol.2021.279012

Cite this

Moreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., Simkovic, M., Novak, J., Strugov, V., Gill, D., Gribben, J. G., Kwei, K., Dai, S., Hsu, E., Dean, J. P., & Flinn, I. W. (2022). First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA , 107(9), 2108-2120. https://doi.org/10.3324/haematol.2021.279012

Moreno, Carol ; Greil, Richard ; Demirkan, Fatih et al. / First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. In: HAEMATOLOGICA 2022 ; Vol. 107, No. 9. pp. 2108-2120.

@article{eec0fca397154bc49da191dacdff8506,

title = "First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.",

keywords = "OPEN-LABEL, CHEMOIMMUNOTHERAPY, MULTICENTER, RITUXIMAB, OUTCOMES",

author = "Carol Moreno and Richard Greil and Fatih Demirkan and Alessandra Tedeschi and Bertrand Anz and Loree Larratt and Martin Simkovic and Jan Novak and Vladimir Strugov and Devinder Gill and Gribben, {John G} and Kevin Kwei and Sandra Dai and Emily Hsu and Dean, {James P} and Flinn, {Ian W}",

note = "Greil, Richard: 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Salzburg, Austria",

year = "2022",

doi = "10.3324/haematol.2021.279012",

language = "English",

volume = "107",

pages = "2108--2120",

journal = "HAEMATOLOGICA ",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "9",

}

Moreno, C, Greil, R, Demirkan, F, Tedeschi, A, Anz, B, Larratt, L, Simkovic, M, Novak, J, Strugov, V, Gill, D, Gribben, JG, Kwei, K, Dai, S, Hsu, E, Dean, JP & Flinn, IW 2022, 'First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.', HAEMATOLOGICA , vol. 107, no. 9, pp. 2108-2120. https://doi.org/10.3324/haematol.2021.279012

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. / Moreno, Carol; Greil, Richard (Co-author); Demirkan, Fatih et al.
In: HAEMATOLOGICA , Vol. 107, No. 9, 2022, p. 2108-2120.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.

AU - Moreno, Carol

AU - Greil, Richard

AU - Demirkan, Fatih

AU - Tedeschi, Alessandra

AU - Anz, Bertrand

AU - Larratt, Loree

AU - Simkovic, Martin

AU - Novak, Jan

AU - Strugov, Vladimir

AU - Gill, Devinder

AU - Gribben, John G

AU - Kwei, Kevin

AU - Dai, Sandra

AU - Hsu, Emily

AU - Dean, James P

AU - Flinn, Ian W

N1 - Greil, Richard: 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Salzburg, Austria

PY - 2022

Y1 - 2022

KW - OPEN-LABEL

KW - CHEMOIMMUNOTHERAPY

KW - MULTICENTER

KW - RITUXIMAB

KW - OUTCOMES

U2 - 10.3324/haematol.2021.279012

DO - 10.3324/haematol.2021.279012

M3 - Original Article

C2 - 35021599

SN - 0390-6078

VL - 107

SP - 2108

EP - 2120

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

IS - 9

ER -

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA . 2022;107(9):2108-2120. doi: 10.3324/haematol.2021.279012